The US Food and Drug Administration has expanded the approved uses of the ADHD drug Vyvanse (lisdexamfetamine dimesylate) to treat “binge-eating disorder” in adults. “The drug is the first FDA-approved medication to treat this condition,” stated an FDA press release.
“Vyvanse was reviewed under the FDA’s priority review program, which provides for an expedited review of drugs that are intended to treat a serious disease or condition and may provide a significant improvement over available therapy,” added the press release.
“Binge eating was only recently added to the American Psychiatric Association’s approved list of mental disorders,” reported the Wall Street Journal. “An estimated 2.8 million adults in the U.S. are binge eaters, two times more than those who have the eating disorders anorexia and bulimia combined, according to Shire. For Shire, the approval could eventually add “several hundred million” dollars in sales, and help the company reach its goal of $10 billion in yearly sales by 2020, said Flemming Ornskov, the company’s chief executive. Vyvanse is the company’s top-selling drug, notching $1.1 billion of the company’s $4.3 billion in total sales during the first nine months of last year.”
“But specialists in the treatment of eating disorders weren’t so sure,” reported International Business Times. “(Binge Eating Disorder) is a complicated disorder, with too many causes and factors to be treated by a single drug, and both Vyvanse and Shire Pharmaceuticals, the drug’s manufacturer, have troubled histories that include illegal marketing and child suicides.”
FDA expands uses of Vyvanse to treat binge-eating disorder (US FDA press release, January 30, 2015)
Shire Drug Cleared to Treat Binge-Eating Disorder (Wall Street Journal, January 30, 2015)
Binge-Eating Disorder Drug: Vyvanse, Controversial ADHD Medication, Approved by FDA (International Business Times, February 6, 2015)